Sort
23,748 grants matching “melanoma”
TARGETING TOLL-LIKE RECEPTORS IN OX40 IN HUMAN MELANOMA
$1,429,995The Univeristy Of Texas M.D. Anderson Cancer Center · · FY2011 · Department of the Army
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment
$1,428,421David E Fisher · Massachusetts General Hospital · P01 · FY2023 · CA
DNA Repair in Human Cancer-Prone Genetic Diseases
$1,428,248Kenneth H Kraemer · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Genomic, Epigenetic and Functional Analyses of Vertebrate Regulatory Regions
$1,427,907Laura L Elnitski · National Human Genome Research Institute · ZIA · FY2014 · HG
Administration And Multicenter Trial Operations Center
$1,426,939Donald L Morton · Saint John'S Cancer Institute · P01 · FY2013 · CA
RXR Rexinoids for Cancer Chemoprevention
$1,426,503Craig A Elmets · University Of Alabama At Birmingham · P01 · FY2019 · CA
Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
$1,424,928Aaron Thomas Gerds · Case Western Reserve University · UG1 · FY2022 · CA
HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients
$1,424,426Stuart J Kahn · Syntrix Biosystems, Inc. · R44 · FY2019 · HL
Program Project Grant
$1,424,168University Of California San Francisco · P01 · FY2004 · AR
Human Melanoma: Etiology, Progression and Therapy
$1,422,871Meenhard Herlyn · Wistar Institute · P01 · FY2015 · CA
Human Melanoma: Etiology, Progression and Therapy
$1,421,890Meenhard Herlyn · Wistar Institute · P01 · FY2012 · CA
Molecular Response and Imaging-based Combination Strategies for Optimal PDT
$1,421,276Tayyaba Hasan · Massachusetts General Hospital · P01 · FY2017 · CA
In vivo efficacy, safety and PK/PD analysis of SYN101, a first in class, immune cell targeted TGFb therapy for cancer patients
$1,420,853Dori A Thomas-Karyat · Synthis Therapeutics, Inc. · R44 · FY2025 · CA
Molecular Response and Imaging-based Combination Strategies for Optimal PDT
$1,419,849Tayyaba Hasan · Massachusetts General Hospital · P01 · FY2016 · CA
Molecular Response and Imaging-based Combination Strategies for Optimal PDT
$1,418,960Tayyaba Hasan · Massachusetts General Hospital · P01 · FY2012 · CA
HUMAN MELANOMA--ETIOLOGY, PROGRESSION AND THERAPY
$1,418,371Wistar Institute · P01 · FY2003 · CA
ANALYSIS OF DOMINANT MEGACOLON--ANOTHER MODEL FORHIRSCHSPRUNG DISEASE
$1,417,834William J Pavan · Human Genome Research · Z01 · FY2007 · HG
Function genomic analysis of neural crest development
$1,417,834William J Pavan · Human Genome Research · Z01 · FY2007 · HG
Integrated analyses of genetics, epigenetics, and gene expression
$1,417,383Maxwell Lee · Division Of Basic Sciences - Nci · ZIH · FY2024 · CA
Mechanisms of non-classical multidrug resistance in cancer
$1,416,959Michael Gottesman · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
The UCLA Center for In Vivo Imaging in Cancer Biology
$1,415,212Harvey R. Herschman · University Of California Los Angeles · P50 · FY2012 · CA
MicroPET/SPECT/CT animal imaging device for translational research
$1,414,616Eugene Fine · Albert Einstein College Of Medicine · S10 · FY2010 · RR
Bioinformatics
$1,412,853Leping Li · National Institute Of Environmental Health Sciences · ZIA · FY2018 · ES
DNA Repair in Human Cancer-Prone Genetic Diseases
$1,412,626Kenneth H Kraemer · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
$1,412,352Aaron Thomas Gerds · Case Western Reserve University · UG1 · FY2025 · CA